Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study.
OBJECTIVE
By protecting and stimulating HIV-specific CD4 cell responses, treatment of primary HIV infection (PHI) with potent quadruple HAART could lead to prolonged suppression of HIV replication after cessation of antiretroviral therapy. The QUEST trial investigates this hypothesis and aims to determine whether addition of a therapeutic vaccine to HAART increases the likelihood of prolonged viral suppression compared to HAART alone.


METHODS
148 patients with PHI were recruited. Participants were treated with open-label HAART for at least 76 weeks. Participants with sustained viremia <50 copies/mL were randomized to one of three 5-month, double-blinded study treatment groups: HAART alone, HAART + ALVAC-HIV (vCP1452), or HAART + ALVAC-HIV (vCP1452) + Remune. After a further month of HAART alone, all treatment was stopped where plasma HIV-1 RNA remained at <50 copies/mL. Intensive virologic and immunologic monitoring during a 24-week observation period followed treatment interruption. Patients who met treatment reintroduction criteria were offered HAART rescue.
Goh
L E
LE
Department of HIV & Opportunistic Infections, GlaxoSmithKline, Research and Development, GlaxoSmithKline, Greenford Road, Greenford, Middlesex, United Kingdom. LG6017@Glaxowellcome.co.uk
Perrin
L
L
Hoen
B
B
Cooper
D
D
Phillips
A
A
Janossy
G
G
Sonnenborg
A
A
Tsoukas
C
C
Lampe
F
F
Kinloch
S
S
D016915:AIDS Vaccines / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D016516:CD4-CD8 Ratio; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D017408:Guidelines as Topic; D015658:HIV Infections / Q000188:drug therapy* / Q000628:therapy* / Q000821:virology; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D012367:RNA, Viral / Q000097:blood; D014765:Viral Vaccines / Q000627:therapeutic use; D014766:Viremia / Q000517:prevention & control
D016915:AIDS Vaccines; C078788:ALVAC vaccine; D019380:Anti-HIV Agents; D012367:RNA, Viral; D014765:Viral Vaccines; C105086:remune